SCM
BCYC

Suvretta Capital Management’s Bicycle Therapeutics BCYC Stock Holding History

Suvretta Capital Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-914,476
Closed -$22.8M – 100
2024
Q1 		$22.8M Hold
914,476
– – 0.85% 38
2023
Q4 		$16.5M Sell
914,476
-96,500
-10% -$1.6M 0.75% 40
2023
Q3 		$20.3M Buy
+1,010,976
New +$23.1M 1.1% 30

Other funds holding BCYC

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Suvretta Capital Management's BCYC Position: Q2 2024 in Review

Suvretta Capital Management sold out of Bicycle Therapeutics (BCYC) in Q2 2024, closing a stake of 914,476 shares — an estimated $22.8M sold.

Suvretta Capital Management first reported a position in BCYC in Q3 2023 and held it in 3 quarters. The position peaked at $22.8M in Q1 2024. 107 funds tracked by Wall St. Rank hold BCYC as of Q2 2024.

  • Suvretta Capital Management reported no remaining Bicycle Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Suvretta Capital Management sold 914,476 Bicycle Therapeutics shares in Q2 2024, an estimated $22.8M.
  • Suvretta Capital Management first reported a position in Bicycle Therapeutics in Q3 2023 and held it in 3 quarters.
  • Suvretta Capital Management's Bicycle Therapeutics position peaked at $22.8M in Q1 2024.
  • 107 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q2 2024.

Based on Suvretta Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.